175 related articles for article (PubMed ID: 22264635)
1. In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling.
Santonico M; Lucantoni G; Pennazza G; Capuano R; Galluccio G; Roscioni C; La Delfa G; Consoli D; Martinelli E; Paolesse R; Di Natale C; D'Amico A
Lung Cancer; 2012 Jul; 77(1):46-50. PubMed ID: 22264635
[TBL] [Abstract][Full Text] [Related]
2. Quantitative breath analysis of volatile organic compounds of lung cancer patients.
Song G; Qin T; Liu H; Xu GB; Pan YY; Xiong FX; Gu KS; Sun GP; Chen ZD
Lung Cancer; 2010 Feb; 67(2):227-31. PubMed ID: 19409642
[TBL] [Abstract][Full Text] [Related]
3. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis.
Chen X; Xu F; Wang Y; Pan Y; Lu D; Wang P; Ying K; Chen E; Zhang W
Cancer; 2007 Aug; 110(4):835-44. PubMed ID: 17599760
[TBL] [Abstract][Full Text] [Related]
4. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
[TBL] [Abstract][Full Text] [Related]
5. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study.
Westhoff M; Litterst P; Freitag L; Urfer W; Bader S; Baumbach JI
Thorax; 2009 Sep; 64(9):744-8. PubMed ID: 19158121
[TBL] [Abstract][Full Text] [Related]
6. Breath testing as a method for detecting lung cancer.
Taivans I; Bukovskis M; Strazda G; Jurka N
Expert Rev Anticancer Ther; 2014 Feb; 14(2):121-3. PubMed ID: 24467216
[TBL] [Abstract][Full Text] [Related]
7. Exhaled biomarkers in lung cancer.
Horváth I; Lázár Z; Gyulai N; Kollai M; Losonczy G
Eur Respir J; 2009 Jul; 34(1):261-75. PubMed ID: 19567608
[TBL] [Abstract][Full Text] [Related]
8. Determination of volatile organic compounds as biomarkers of lung cancer by SPME-GC-TOF/MS and chemometrics.
Rudnicka J; Kowalkowski T; Ligor T; Buszewski B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3360-6. PubMed ID: 21982505
[TBL] [Abstract][Full Text] [Related]
9. Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer.
Nardi-Agmon I; Abud-Hawa M; Liran O; Gai-Mor N; Ilouze M; Onn A; Bar J; Shlomi D; Haick H; Peled N
J Thorac Oncol; 2016 Jun; 11(6):827-37. PubMed ID: 26968885
[TBL] [Abstract][Full Text] [Related]
10. The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs.
Capuano R; Santonico M; Pennazza G; Ghezzi S; Martinelli E; Roscioni C; Lucantoni G; Galluccio G; Paolesse R; Di Natale C; D'Amico A
Sci Rep; 2015 Nov; 5():16491. PubMed ID: 26559776
[TBL] [Abstract][Full Text] [Related]
11. Organic metabolites in exhaled human breath--a multivariate approach for identification of biomarkers in lung disorders.
Gaspar EM; Lucena AF; Duro da Costa J; Chaves das Neves H
J Chromatogr A; 2009 Apr; 1216(14):2749-56. PubMed ID: 19036381
[TBL] [Abstract][Full Text] [Related]
12. Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease.
Zou Y; Zhang X; Chen X; Hu Y; Ying K; Wang P
Cancer Biomark; 2014; 14(5):371-9. PubMed ID: 25171479
[TBL] [Abstract][Full Text] [Related]
13. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS.
Poli D; Goldoni M; Corradi M; Acampa O; Carbognani P; Internullo E; Casalini A; Mutti A
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Oct; 878(27):2643-51. PubMed ID: 20149763
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary haptoglobin: a new marker for adenocarcinomas of the lung?
Abdullah M; Marwitz S; Kähler D; Schultz H; Kugler C; Zabel P; Vollmer E; Goldmann T
Pathology; 2011 Jan; 43(1):70-2. PubMed ID: 21240070
[No Abstract] [Full Text] [Related]
15. An investigation on electronic nose diagnosis of lung cancer.
D'Amico A; Pennazza G; Santonico M; Martinelli E; Roscioni C; Galluccio G; Paolesse R; Di Natale C
Lung Cancer; 2010 May; 68(2):170-6. PubMed ID: 19959252
[TBL] [Abstract][Full Text] [Related]
16. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.
Terry J; Leung S; Laskin J; Leslie KO; Gown AM; Ionescu DN
Am J Surg Pathol; 2010 Dec; 34(12):1805-11. PubMed ID: 21107086
[TBL] [Abstract][Full Text] [Related]
17. Application of an artificial neural network model for selection of potential lung cancer biomarkers.
Ligor T; Pater Ł; Buszewski B
J Breath Res; 2015 May; 9(2):027106. PubMed ID: 25944812
[TBL] [Abstract][Full Text] [Related]
18. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD.
Dragonieri S; Annema JT; Schot R; van der Schee MP; Spanevello A; Carratú P; Resta O; Rabe KF; Sterk PJ
Lung Cancer; 2009 May; 64(2):166-70. PubMed ID: 18834643
[TBL] [Abstract][Full Text] [Related]
19. The application of statistical methods using VOCs to identify patients with lung cancer.
Ulanowska A; Kowalkowski T; Trawińska E; Buszewski B
J Breath Res; 2011 Dec; 5(4):046008. PubMed ID: 22071773
[TBL] [Abstract][Full Text] [Related]
20. Influences of mixed expiratory sampling parameters on exhaled volatile organic compound concentrations.
Thekedar B; Oeh U; Szymczak W; Hoeschen C; Paretzke HG
J Breath Res; 2011 Mar; 5(1):016001. PubMed ID: 21383425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
